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LETTERS TO THE EDITOR
Failure of Topical Estrogen Receptor Agonists and Antagonists
to Alter Murine Hair Follicle Cycling
To the Editor:
In October 1996 there appeared a publication by Oh and Smart
describing experiments that were interpreted to indicate an important
estrogen receptor regulation of hair growth. This report was well
publicized and stimulated a worldwide response.
In essence, the report indicated that in the CD-1 female mouse
topical 17β estradiol, but not 17α estradiol, blocks anagen induction
and that the estrogen receptor antagonist, ICI 182780, induces anagen.
This finding was of major interest to us in the field of hair biology
because the conclusions implied that the hair growth cycle is under
negative control, an idea that we have previously considered (Paus
et al, 1990, 1991; Stenn et al, 1993). For this reason we made a
concentrated attempt in two independent and widely separated laborat-
ories to reproduce the experiments as they were described. At the
outset we recognized that the putative capacity of 17β estradiol to
‘‘arrest’’ hair follicles in telogen as suggested by Oh and Smart
contradicted the clinical use of topical estradiol for the successful
treatment of telogen effluvium in humans, presumably by prolonging
the duration of anagen (Orfanos and Vogel, 1980).
In our studies we used two pigmented female mouse strains, C57BL/
6 and C3H, because (i) we wanted to test the phenomenon in two
different mouse strains, and (ii) we have found that careful hair cycle
studies using a nonpigmented animal, such as the CD-1 mouse, are
very difficult to interpret.
In Experiment I, we treated the animals following the Oh/Smart
protocol precisely. For the induction study hair-clipped animals were
treated twice weekly for 7 wk [ICI 182780, 10 nM, as well as
Tamoxifen, 10 nM (Sigma, St Louis, MO)]. For the inhibition studies,
anagen was depilatory-cream-induced (NeetTM) and the mice were
treated twice weekly with 17α estradiol (10 nM, Sigma) or 17β
estradiol (10 nM, Sigma) for 2 wk. In addition, we treated hair-clipped
mice with all back skin follicles in telogen, and treated them with
either 17β estradiol, 17α estradiol, or vehicle alone, twice weekly for
5 wk. Each experimental group contained 5–7 mice and was repeated
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On Photo-Stability of Oxybenzone
To the Editor:
I refer to a paper by Schallreuter et al. (1996) entitled ‘‘Oxybenzone
oxidation following solar irradiation of skin: photoprotection versus
antioxidant inactivation’’ that was published in the March issue of
Journal of Investigative Dermatology. In this paper it is suggested that
oxybenzone (2-hydroxy-4-methoxy benzophenone) is unstable to
sunlight: there is a significant increase of the CO group concentration
indicative of the oxidation of oxybenzone to its semiquinone. This
conclusion encouraged us to perform some investigation by Fourier
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once. On completion, in no experiment were the treated mice
significantly different from the controls.
In Experiment II, the estradiol studies were repeated using the same
preparations as in Experiment I but the drugs were applied daily for
2 wk. Again, experimental animals showed no difference from controls.
In Experiment III, conditions were identical to Experiment I but the
applications of the receptor antagonists [ICI 182780 or Tamoxifen,
10 nM (Sigma)] or the agonists (17α estradiol and 17β estradiol) were
given daily for 20 d (antagonists) and 9 d (agonists). Again, the
experimental mice showed no difference from the controls.
It is always difficult to interpret a negative result. One possibility in
explaining these discrepancies is that the phenomena described are
unique to the animal strain used, namely, CD-1. Nevertheless, whatever
the complete explanation for the differences observed in the three
laboratories, the experiments reported here indicate that the estrogen
effects are not applicable to two of the mouse strains routinely used in
hair research, and conflict with common clinical experience. The Oh
and Smart (1996) conclusions on the role of estrogen receptor
stimulation or blockade in hair growth control therefore will require
rigorous further testing and analysis before they can be critically
accepted.
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Transform Infrared Spectroscopy (FTIR) on the stability to light of
oxybenzone.
An acetone solution of the product was deposited on sodium
chloride windows and on a KRS-5 crystal. The solvent was evaporated
and a very thin layer of the product obtained. The layer on the crystal
was exposed to sunlight for 2 h and the layer on the sodium choride
windows was exposed to light in a Suntest CPS1 apparatus (Xenotest
GmbH, Hanau, D) for 15 h. The multiple internal reflectance FTIR
spectrum of the layer on the crystal and the transmission FTIR
